Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Predictors of Future Nonadherence in Inflammatory Bowel Disease.
Severs M, Mangen MJ, Fidder HH, van der Valk ME, van der Have M, van Bodegraven AA, Clemens CHM, Dijkstra G, Jansen JM, de Jong DJ, Mahmmod N, van de Meeberg PC, van der Meulen-de Jong AE, Pierik M, Ponsioen CY, Romberg-Camps MJL, Siersema PD, Jharap B, van der Woude JC, Zuithoff NPA, Oldenburg B. Severs M, et al. Among authors: van der woude jc. Inflamm Bowel Dis. 2017 Sep;23(9):1568-1576. doi: 10.1097/MIB.0000000000001201. Inflamm Bowel Dis. 2017. PMID: 28700534
Guidelines for treatment with infliximab for Crohn's disease.
Hommes DW, Oldenburg B, van Bodegraven AA, van Hogezand RA, de Jong DJ, Romberg-Camps MJ, van der Woude J, Dijkstra G; Dutch Initiative on Crohn and Colitis (ICC). Hommes DW, et al. Neth J Med. 2006 Jul-Aug;64(7):219-29. Neth J Med. 2006. PMID: 16929083 Free article. Review.
Genetic analysis in a Dutch study sample identifies more ulcerative colitis susceptibility loci and shows their additive role in disease risk.
Festen EA, Stokkers PC, van Diemen CC, van Bodegraven AA, Boezen HM, Crusius BJ, Hommes DW, van der Woude CJ, Balschun T, Verspaget HW, Schreiber S, de Jong DJ, Franke A, Dijkstra G, Wijmenga C, Weersma RK. Festen EA, et al. Am J Gastroenterol. 2010 Feb;105(2):395-402. doi: 10.1038/ajg.2009.576. Epub 2009 Oct 27. Am J Gastroenterol. 2010. PMID: 19861958
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, Sands BE, Hanauer SB, Targan S, Rutgeerts P, Ghosh S, de Villiers WJ, Panaccione R, Greenberg G, Schreiber S, Lichtiger S, Feagan BG; CERTIFI Study Group. Sandborn WJ, et al. N Engl J Med. 2012 Oct 18;367(16):1519-28. doi: 10.1056/NEJMoa1203572. N Engl J Med. 2012. PMID: 23075178 Free article. Clinical Trial.
Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial.
Ponsioen CY, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Bossuyt PMM, Hart A, Warusavitarne J, Buskens CJ, van Bodegraven AA, Brink MA, Consten ECJ, van Wagensveld BA, Rijk MCM, Crolla RMPH, Noomen CG, Houdijk APJ, Mallant RC, Boom M, Marsman WA, Stockmann HB, Mol B, de Groof AJ, Stokkers PC, D'Haens GR, Bemelman WA; LIR!C study group. Ponsioen CY, et al. Lancet Gastroenterol Hepatol. 2017 Nov;2(11):785-792. doi: 10.1016/S2468-1253(17)30248-0. Epub 2017 Aug 31. Lancet Gastroenterol Hepatol. 2017. PMID: 28838644 Clinical Trial.
Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease.
Spekhorst LM, Oldenburg B, van Bodegraven AA, de Jong DJ, Imhann F, van der Meulen-de Jong AE, Pierik MJ, van der Woude JC, Dijkstra G, D'Haens G, Löwenberg M, Weersma RK, Festen EAM; Parelsnoer Institute and the Dutch Initiative on Crohn and Colitis. Spekhorst LM, et al. Among authors: van der woude jc. World J Gastroenterol. 2017 Dec 14;23(46):8182-8192. doi: 10.3748/wjg.v23.i46.8182. World J Gastroenterol. 2017. PMID: 29290654 Free PMC article.
Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease.
D'Haens G, Vermeire S, Lambrecht G, Baert F, Bossuyt P, Pariente B, Buisson A, Bouhnik Y, Filippi J, Vander Woude J, Van Hootegem P, Moreau J, Louis E, Franchimont D, De Vos M, Mana F, Peyrin-Biroulet L, Brixi H, Allez M, Caenepeel P, Aubourg A, Oldenburg B, Pierik M, Gils A, Chevret S, Laharie D; GETAID. D'Haens G, et al. Gastroenterology. 2018 Apr;154(5):1343-1351.e1. doi: 10.1053/j.gastro.2018.01.004. Epub 2018 Jan 6. Gastroenterology. 2018. PMID: 29317275 Free article. Clinical Trial.
Sex-Related Differences in Patients With Inflammatory Bowel Disease: Results of 2 Prospective Cohort Studies.
Severs M, Spekhorst LM, Mangen MJ, Dijkstra G, Löwenberg M, Hoentjen F, van der Meulen-de Jong AE, Pierik M, Ponsioen CY, Bouma G, van der Woude JC, van der Valk ME, Romberg-Camps MJL, Clemens CHM, van de Meeberg P, Mahmmod N, Jansen J, Jharap B, Weersma RK, Oldenburg B, Festen EAM, Fidder HH. Severs M, et al. Among authors: van der woude jc. Inflamm Bowel Dis. 2018 May 18;24(6):1298-1306. doi: 10.1093/ibd/izy004. Inflamm Bowel Dis. 2018. PMID: 29688413
Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIR!C Trial.
de Groof EJ, Stevens TW, Eshuis EJ, Gardenbroek TJ, Bosmans JE, van Dongen JM, Mol B, Buskens CJ, Stokkers PCF, Hart A, D'Haens GR, Bemelman WA, Ponsioen CY; LIR!C study group. de Groof EJ, et al. Gut. 2019 Oct;68(10):1774-1780. doi: 10.1136/gutjnl-2018-317539. Epub 2019 Feb 1. Gut. 2019. PMID: 31233395 Clinical Trial.
Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial.
Stevens TW, Haasnoot ML, D'Haens GR, Buskens CJ, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Mol B, Stokkers PCF, Bemelman WA, Ponsioen CY; LIR!C study group. Stevens TW, et al. Lancet Gastroenterol Hepatol. 2020 Oct;5(10):900-907. doi: 10.1016/S2468-1253(20)30117-5. Epub 2020 Jun 30. Lancet Gastroenterol Hepatol. 2020. PMID: 32619413 Clinical Trial.
36 results